Thanks for the current report. Definitely helps clarify and confirm some info from AT1's qtrly.
I am not seeing where it says that 25k unit rev was not booked. Could you pls point me to it?
OR maybe you meant the '259k' sale rev share portion that was not booked? I did read that and we should not be expecting anyway to see this in Q3 rev, as AT1 co-branded tests can't be sold in US yet, which this report also confirms (Access Bio would only handover sales rev cash after a confirmed sale).
Thus, I don't think this 259k sale rev portion is connected to the Q2 missing Trade n Receivables $ - since AT1 was not counting any AccessBio base unit price till Q3 nor any additonal sales rev till sales are made.....so none of this could have shown up in Q2 pending invoices already? So it has to something else still pending payment/adjustment from Q2, in my view.
Cannacord report doesn't indicate any Q2 pending vs Q3 cash receipt discrepancy...so it re-affirms my thinking that I shouldn't be too fussed by it (yet). Those missing Receivable $ have to be present in the overall FY21 balance sheet and be accounted for by 30 June.
Regardless, as RNClarke mentioned, all of this past data + forward approval hope + Q1-Q2 rev trend has definitely led to higher assumptions by analysts + retail investors like us...which has driven the SP selling downtrend. Its good to be able to understand and confirm this via an stock analyst PoV.
